Study details
Enrolling now
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
Brigham and Women's Hospital
NCT IDNCT06441604ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 9 months
Ages
18+
Locations
1 site in MA
About this study
This trial is testing extended-release buprenorphine (XR-BUP) as a new way to start treatment for opioid use disorder. Participants will receive fentanyl to prevent withdrawal symptoms, followed by an injection of XR-BUP and monitoring for any withdrawal effects.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Extended-release Buprenorphine
PhasePhase 2
DrugExtended-release Buprenorphine
Routesublingual
Primary goalPlasma-concentration curves (AUC) of buprenorphine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
buprenorphine
Drug routes
sublingual
Endpoints
Primary: Plasma-concentration curves (AUC) of buprenorphine., Safety and tolerability of XR-Buprenorphine
Secondary: Elimination half-life
Body systems
Psychiatry / Mental Health